These series included patients with multifocal and bilateral tumors and those with large tumors (>4 cm), supporting the initial finding of indolent clinical behavior of NIFTP.
However, 2 other studies reported that 4% to 6% of patients with nodules meeting the diagnostic criteria for NIFTP were found to have metastasis. 5, 6 Many of these tumors had at least some papillary structures identified, revealed BRAF V600E mutation, and showed metastasis to regional lymph nodes and not distant sites. All of these features are characteristics of classic papillary thyroid carcinoma (PTC) and are rarely seen in an invasive encapsulated follicular variant of PTC, which is an invasive counterpart of NIFTP. The initial report that established NIFTP as a preinvasive form of encapsulated follicular variant PTC demonstrated that both tumor types typically harbor RAS or other RAS-like mutations and not BRAF V600E, and if invasion develops, the tumors metastasized to distant sites and not the regional lymph nodes. 1 This finding raises a concern that incorrect application of diagnostic criteria for NIFTP can lead to misdiagnosis of classic PTC with prominent follicular pattern as NIFTP. The initially proposed diagnostic criteria for NIFTP allowed for less than 1% papillae.
1 However, the intention of the authors was to accept single rudimentary, hyperplastictype papillae and not true papillae with well-developed nuclear features seen in classic PTC. In light of the recent publications, it is likely that a broader use of the "less than 1% papillae" criterion can lead to diagnosing tumors with biological and clinical characteristics of classic PTC as NIFTP.
Discussion | Although several studies published since the initial NIFTP report attest to low malignant potential of this tumor, cases of several patients with micrometastasis in regional lymph nodes and tumors apparently meeting the proposed diagnostic criteria for NIFTP have been reported. To avoid misdiagnosing these tumors as NIFTP, we propose to substitute the criterion of "less than 1% papillae" with the criterion of "no well-formed papillae" (Box). Furthermore, we suggest that in addition to a strict requirement for examination of the entire tumor capsule in tumors with pronounced nuclear features of PTC (nuclear score 3), 1 examination of the entire tumor should be performed to exclude the presence of papillary structures. This proposal is based on the fact that NIFTP more frequently shows moderately expressed nuclear features of PTC (nuclear score 2) and their overt presence should raise a suspicion for classic PTC. If molecular or immunohistochemical testing demonstrates mutations typical of classic PTC, such as BRAF V600E or other BRAF V600E-like mutations (eg, RET/PTC fusions) or high-risk mutations, such as TERT, this should trigger an 
